

Comparison of human papillomavirus (HPV) detection in urine and cervical swab samples using the HPV GenoArray Diagnostic assay

Pornjarim Nilyanimit¹, **Jira Chansaenroj**¹, **Anant Karalak**², **Piyawat Laowahutanont**³, **Pairoj Junyangdikul**⁴, **Yong Poovorawan**^{Corresp. 1}

¹ Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

² Department of Pathology, National Cancer Institute, Bangkok, Thailand

³ Department of Gynecology, National Cancer Institute, Bangkok, Thailand

⁴ Department of Pathology, Samitivej Srinakarin Hospital, Bangkok Hospital Group, Bangkok, Thailand

Corresponding Author: Yong Poovorawan

Email address: Yong.P@chula.ac.th

Human papillomavirus (HPV) is the leading cause of cervical cancer. Urine-based HPV testing offers a simple and non-invasive method because of its increasing acceptance. A total of 164 pairs of cervical swab and urine samples from Thai women who underwent cervical cancer screening were used for HPV testing with HPV GenoArray Diagnostic Kits. The overall concordance percentage for HPV detection in the cervical swab and urine samples was 65.2%. The HPV genotypes most commonly detected were HPV16 and HPV18. An analysis of the urine samples and a second analysis of the cervical swab samples showed that the differences in the overall HPV detection rate between women with normal and abnormal cytology were not significant ($p > 0.05$). Urine samples processed with the GenoArray assay is an alternative for women who decline to undergo Pap smear even though it is not ideal as the first-line screening option.

1 Comparison of human papillomavirus (HPV) detection in urine and cervical swab samples
2 using the HPV GenoArray Diagnostic assay

3 Pornjarim Nilyanimit¹, Jira Chansaenroj¹, Anant Karalak², Piyawat Laowahutanont³, Pairoj
4 Junyangdikul⁴, Yong Poovorawan^{1*}

5 Author Details

6 ¹Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,
7 Chulalongkorn University, Bangkok, Thailand

8 ²Department of Pathology, National Cancer Institute, Bangkok, Thailand

9 ³Department of Gynecology, National Cancer Institute, Bangkok, Thailand

10 ⁴Department of Pathology, Samitivej Srinakarin Hospital, Bangkok Hospital Group, Bangkok,
11 Thailand

12 Running Head: HPV detection in urine using GenoArray

13 Keywords: HPV, genotyping, cervical cancer, urine

14 *Corresponding author: Prof. Yong Poovorawan

15 E-mail: Yong.P@chula.ac.th

16 **ABSTRACT**

17 Human papillomavirus (HPV) is the leading cause of cervical cancer. Urine-based HPV testing
 18 offers a simple and non-invasive method because of its increasing acceptance. A total of 164 pairs
 19 of cervical swab and urine samples from Thai women who underwent cervical cancer screening
 20 were used for HPV testing with HPV GenoArray Diagnostic Kits. The overall concordance
 21 percentage for HPV detection in the cervical swab and urine samples was 65.2%. The HPV
 22 genotypes most commonly detected were HPV16 and HPV18. An analysis of the urine samples
 23 and a second analysis of the cervical swab samples showed that the differences in the overall
 24 HPV detection rate between women with normal and abnormal cytology were not significant ($p >$
 25 0.05). Urine samples processed with the GenoArray assay is an alternative for women who
 26 decline to undergo Pap smear even though it is not ideal as the first-line screening option.

27 INTRODUCTION

28 Human papillomavirus (HPV) causes cervical cancer (*Koutsky, 1997*). Approximately 170
29 genotypes have been identified (*De Villiers et al., 2004*) and at least 40 genotypes infect the
30 human anogenital tract (*De Villiers, 2013*). The genital HPVs are classified into high-risk and
31 low-risk genotypes depending on their association with uterine cervical cancer (*Muñoz et al.,*
32 *2003*). The high-risk genotypes most commonly detected in uterine cervical cancer are HPV16,
33 18, 31, 33, 35, 45, 52, 58, 39, 51, 56, and 59 (*Bouvard et al., 2009*).

34 The incidence of cervical cancer in young women is increasing in many countries due to
35 improved awareness and testing. HPV prevalence in Asia, Africa, Europe and South America
36 varied significantly depending on the population and geographical regions (*Clifford et al., 2005*).
37 In Europe, it ranges from 1.4% (Spain) to 9.2% (Italy). In South America, the prevalence ranged
38 from 11.9% (Chile) to 16.3% (Argentina). In Southeast Asia, the prevalence ranged from 1.6%
39 (Vietnam) to 13.3% (Korea). Even within a country such as Thailand, HPV prevalence can vary
40 from 7.2% in northern region to 15.1% in central region (*Kantathavorn et al., 2015*).

41 The Papanicolaou (Pap) test is a cost-effective way to screen for cervical cancer. Test results
42 help physicians detect precancerous lesions and determine the course of treatment. Pap test has
43 been shown to reduce the incidence of mortality from cervical cancer (*Mählck et al., 1994*).
44 However, it is primarily used for detecting invasive cervical cancer and cannot identify
45 asymptomatic HPV infection (*Safaeian et al., 2007; Leyden et al., 2005*). In addition, barriers to
46 testing include the lack of information, personal preference, fear, embarrassment and lack of trust
47 in healthcare under certain circumstances. False information regarding the procedure, the lack of
48 spousal support towards screening, cultural taboos, and stigmatization of women with cervical
49 cancer further contribute to the limitations of the Pap test. Therefore, alternative and

supplementary HPV DNA assays are often required in combination with the traditional Pap smear test (Cox *et al.*, 1995).

HPV DNA detection in urine samples presents a feasible alternative to HPV DNA detection in cervical specimens. Urine testing provides an especially simple, non-invasive method for screening (Prusty *et al.*, 2005). The benefits of using urine for HPV DNA detection have been evaluated in disease surveillance and screening for cervical cancers involving specific genotypes. HPV DNA urine testing can be used to identify abnormal cells in adolescent girls and young women who do not wish to have a vaginal examination (Vorsters *et al.*, 2014; Enerly *et al.*, 2013). Some studies have reported a high HPV detection sensitivity for urine-based assays (Forshund *et al.*, 1993; Hagihara *et al.*, 2016; Bernal *et al.*, 2014), while other studies have reported a low HPV detection sensitivity from urine-based assays (D'Hauwers *et al.*, 2007; Nilyanimit *et al.*, 2013).

Molecular methods for HPV testing have been explored, such as PCR/sequencing (De Roda Husman *et al.*, 1995), the INNO-LiPA HPV Assay (Van Hamont *et al.*, 2006), and the Hybrid Capture 2 test (HCII) assay (Kubota *et al.*, 1998). In addition, the HPV GenoArray Diagnostic Kit (Hybribio Ltd., Sheung Wan, Hong Kong) is a recently developed PCR-based HPV genotyping assay, which uses L1 consensus primers to amplify 21 HPV genotypes. It is then followed by flow-through hybridization with immobilized genotype-specific probes. This test is currently used in several hospitals in China (Liu *et al.*, 2010). A previous study showed that the sensitivity of the HPV GenoArray assay was 97.8% and the specificity was 100%. (Juan *et al.*, 2013). If its use expanded to other parts of Asia where individuals share similar cultural beliefs, more women would benefit from increased cervical cancer screening. This study aimed to evaluate the use of a urine-based assay as a non-invasive method for HPV detection and to genotype the samples using the HPV GenoArray assay in a Thai population.

74 MATERIALS & METHODS

75 The research protocol was approved by the Ethics Committee of the National Cancer Institute,
76 Thailand (number EC COA 037/2012), and the Institutional Review Board of the Faculty of
77 Medicine at Chulalongkorn University (number 389/2555). The objective of the study was
78 explained to the patients, and written consent was obtained from all participants. Each specimen
79 was sent for testing anonymously, which only included participant-specific numerical code and
80 age information.

81 Clinical specimens

82 All patients underwent the Pap smears test and were subsequently asked to participate in this
83 study. In all, 164 women consented and were willing to provide paired specimens (a Pap smear
84 sample from the cervix and a first-void urine sample). All specimen were recruited between
85 March to December 2014. Specimens were classified into three groups: 95 samples indicating
86 normal cytology, 50 samples indicating low-grade squamous intraepithelial lesions (LSIL), and
87 19 samples indicating high-grade squamous intraepithelial lesions (HSIL). The ages of the
88 patients enrolled in this study were between 19 and 69 years.

89 Sample preparation

90 Each Pap smear sample (which are the standard samples for HPV genotyping) was evaluated by a
91 specialized cytotechnologist and the results were confirmed by a pathologist. Samples were
92 suspended in the liquid-based cytology (LBC) buffer (ThinPrep, Hologic, Marlborough, MA,
93 USA). Collection of the first-void urine (FVU) samples was performed in a sterile Cell PrepPlus
94 (Biodyne, Gyeonggi-do, Korea) urine bottle, stored at 4 °C, and processed within 3 days. For
95 each sample, approximately 15 mL of LBC and FVU were centrifuged at 3,000 rpm for 5 min,
96 and the supernatant was removed. The residual 800 µL of the sample suspension containing cell

debris was washed and centrifuged at 8,000 rpm for 5 min. The DNA was extracted from the pellets using a DNA Prep Kit (Chaozhou HybriBio Biochemistry Ltd., Guangdong, China) and stored at -20°C until testing.

HPV GenoArray Diagnostic Assay

The extracted DNA from the cervical swab and urine samples was subjected to an HPV genotyping assay using HPV GenoArray Diagnostic Kits (HybriBio Ltd., Sheung Wan, Hong Kong) according to the manufacturer's instructions. This PCR-based assay enables the amplification of 21 HPV genotypes including 13 high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), two probable high-risk types (HPV 53 and 66), and six low-risk or unknown risk types (HPV 6, 11, 42, 43, 44, and CP8304 [HPV-81]). This assay uses an L1 consensus primer-based PCR and is different from the Linear Array HPV Genotyping Test, which uses MY09 and MY11 primers (*Liu et al., 2010*). After PCR amplification, the amplicons were subjected to flow-through hybridization on a nylon membrane covered in immobilized HPV genotype-specific oligonucleotide probes. The hybrids were detected by the addition of streptavidin-horseradish peroxidase conjugate and substrate (NBT/BCIP). The presence of a positive result for the internal control and the biotin dots within the membrane serves to validate DNA quality, good enzyme conjugate, and successful hybridization process. Results were manually interpreted using the manufacturer's guidelines. The normal detection limit is ~500 copies/μL of target HPV DNA. There were no cross-reactivities from the amplification/detection of the 21 HPV genotypes. The provided positive control and two negative controls (including HPV-negative C33-A cells) were included in each set of PCR to assess the performance of the test.

Statistical methods

120 A statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
 121 Pearson's chi-square test for matched pairs was used to compare the performance of the two types
 122 of samples regarding the detection of HPV genotypes. Statistical significance was defined as
 123 $p < 0.05$.

RESULTS

The mean age of the 164 participants was 45.8 years. Among the women with normal cytology, the mean age was 50.5 years, while among those with abnormal cytology (LSIL or HSIL), the mean age was 41.1 years. Results from the cervical swab samples showed that 39.6% (65/164) were HPV DNA-positive (Table 1). In total, 11% (18/164) contained multiple HPV genotypes. The most common HPV genotypes detected were HPV16 (12 samples) and HPV18 (8 samples). Thus, 12.2% (20/164) contained either HPV16 or HPV18. In the normal cytology group, 11 of the 95 samples (11.6%) were HPV DNA-positive. In contrast, the LSIL and HSIL groups had 35 (10.0%) and 19 (100.0%) HPV DNA-positive samples, respectively.

For the urine samples, 32.3% (53/164) were HPV DNA-positive (Table 1), of which 7.9% (13/164) had multiple HPV genotypes. The most commonly detected HPV genotypes were HPV18 (17 samples) and HPV16 (four samples). In total, 12.2% (20/164) contained HPV16 or HPV18. In the normal cytology group, 10 of the 95 samples (10.5%) were HPV DNA-positive. In contrast, the LSIL and HSIL groups had 35 (10.0%) and 8 (42.1%) HPV DNA-positive samples, respectively.

We next compared HPV detection efficacy between the standard Pap smear samples and the urine samples. Comparison between the cervical swab and urine specimen resulted in the overall concordance of 65.2% (107/164) (Table 1). In the normal cytology group, the concordance was 71.6% (68/95). In the abnormal cytology group, the concordance was 56.5% (39/69). Using the Pap smear results as reference, the sensitivity and specificity of the urine-based HPV GenoArray Detection Kit were 56.5% and 70.6%, respectively. However, these results were lower than other studies (Table 2). The positive and negative predictive values were 53.8% (95% CI = 41.9 to 65.4) and 72.7% (95% CI = 63.2 to 80.5), respectively.

For multiple HPV infections, the cervical swab-based assays were able to detect more HPV genotypes in each sample. However, in the normal cytology group, for each pair of biospecimens,

the most common number of genotypes per sample was one. Similarly, in the abnormal cytology group, 36 of the 69 cervical swab samples (52.2%) and 31 of the 69 urine samples (44.9%) had a single genotype (Table 3).

An analysis of the urine samples and a second analysis of the cervical swab samples showed that the differences in the overall HPV detection rate between the normal and abnormal cytology groups were not significant ($p > 0.05$).

DISCUSSION

Despite the benefits offered by the Pap test, screening attendance remains low (*Gakidou et al., 2008*), while the estimated incidence of invasive cervical cancer remains high (*Leyden et al., 2005*). In Thailand, 25–38% of women aged 30–65 years have had only one Pap test (*Sriamporn et al., 2006*). When cervical testing for HPV is required, these results suggest that urine sample collection provides an alternative non-invasive sampling method for monitoring HPV infection in women. In a previous study, the overall percentage agreement between HPV detection in urine and cervical samples was 88% using Cobas 4800 HPV test (*Bernal et al., 2014*), 75% using electrochemical DNA chip (*Nilyanimit et al., 2013*) and, in this study, the percentage was 65.2%. The undeniable advantage in testing urine sample is its acceptance and convenience for the patients, although better results are obtained with first urine in the morning (*Vorstors et al., 2014*). However, the results must be interpreted with caution owing to variations among the studies in terms of the participant characteristics, surrogate nature of using cervical HPV detection to screen for cervical disease, and lack of standardized urine testing methods.

Urine sample assays cannot be used to detect all of the genital HPV infections, but these assays provide an alternative for use in epidemiological surveys in which invasive sampling is difficult to perform. Under these circumstances, testing urine for HPV DNA offers a distinct advantage (*Prusty et al., 2005*). Previous studies have compared HPV detection rates between cervical and urine samples in order to evaluate the ability of urine-based assays to detect the prevalence of HPV independently of cervical cytology assays (*Daponte et al., 2006; Munoz et al., 2013*). Evidence suggests that the sensitivity of urine testing for HPV 16 and 18 was higher for participants with cervical cancer (88.8%) than for those with high- and low-grade lesions (*Daponte et al., 2006*). However, since our samples comprised more of normal than abnormal cytology, proportion of HPV16-positive samples are thus admittedly lower in this study. The larger-scale HPV genotyping for cervical cancer screening in China showed the most common

high risk HPV genotypes in women population worldwide were HPV16, 18, 31, 58, 52, 51 and 33, however frequencies varied by region (*de Sanjosé et al.*, 2007). In contrast, some regions showed that HPV52 is higher detection than HPV16 because of the geographical and biological interaction between HPV genotypes and host immunogenic factors (*de Sanjosé et al.*, 2007; *Ye et al.*, 2010). Alternatively, it is possible that certain urine samples yield low-efficiency amplification due to the presence of inhibitory substances in the urine or HPV DNA loss during processing (*Brinkman et al.*, 2004).

The HPV DNA analysis of urine samples needs to be developed further before a urine-based assay can replace the Pap smear test. It is possible that a greater amount of urethral cells in the urine samples helped to increase the sensitivity of the test. An analysis of the urine samples and a second analysis of the cervical swab samples showed that the differences in the overall HPV detection rate between women with normal and abnormal cytology were not significant ($p > 0.05$). This result suggests that urine represents a viable substitute for cervical swabs. However, the urine samples should be optimized by preventing DNA degradation during extraction and storage, recovering cell-free HPV DNA in addition to cell-associated DNA, processing a sufficient volume of urine, and collecting the first portion of the urine stream in the morning (*Vorsters et al.*, 2014).

Using traditional cytological analysis, it is difficult to determine accurate screening results for HPV-associated anogenital tumors. Therefore, HPV genotyping is an alternative screening method to be used in combination with traditional cytology for identifying patients at high risk of developing squamous cell carcinoma (*Saslow et al.*, 2012; *WHO*, 2013). Nowadays, there are many HPV genotyping techniques for detecting HPV DNA, such as PCR, real-time PCR, restriction fragment length polymorphism (RFLP), Hybrid Capture, and Linear Array (*Bernard et al.*, 1994; *Cox et al.*, 1995; *Castle et al.*, 2008). However, PCR and real-time PCR need specific expensive equipment (such as a thermal cycler), and these methods have not yet become common

procedures in hospital laboratories (*Hagiwara et al., 2007*). This study used the HPV GenoArray Diagnostic Kit for HPV genotyping, which is a commercial kit that has recently been started to be used, especially in China (*Liu et al., 2010*). The results from the HPV GenoArray assay used in this study were a percentage-point (39.6%) higher compared to the results from a previous survey of Thai women (7.6%) (*Chansaenroj et al., 2010*) and one of Japanese women (22.5%) (*Onuki et al., 2009*). The higher percentage may be due to the small number of participants in our study sample.

The Linear Array HPV Genotyping Test has been widely used as a standard reference method for evaluating new methods. However, the HPV GenoArray Diagnostic Kit is an alternative technique for studies conducted in resource-limited laboratories because the cost of the HPV GenoArray Diagnostic Kit is lower than that of the Linear Array HPV Genotyping Test and the hybridization time is also lower (*Li et al., 2012; Liu et al., 2010*). Moreover, the HPV GenoArray assay can distinguish and identify HPV 52, which is one of the most common high-risk HPV genotypes in women in eastern and southeastern Asia (*Sukvirach et al., 2003; Takehara et al., 2011*).

In conclusion, the HPV GenoArray assay is an alternative for HPV genotyping using both cervical swab and urine samples, the latter of which is an alternative for women declining to undergo Pap smear. Although it is not the gold standard, utilization of this method is expected to will be increase the number of women who undergo cervical cancer screening.

ACKNOWLEDGEMENTS

We thank the staff of the Center of Excellence in Clinical Virology for their generous assistance.

Funding

228 This work was supported by the National Research Council of Thailand, the Research Chair
229 Grant from NSTDA, the Center of Excellence in Clinical Virology (GCE 59-009-30-005) and
230 King Chulalongkorn University, the Centenary Academic Development Project (CU56-HR01),
231 the Ratchadaphiseksomphot Endowment Fund of Chulalongkorn University (RES560530093),
232 Office of Higher Education Commission (NRU 59-002-HR) and Dutsadi Piphat Scholarship.

233 **Grant Disclosures**

234 The National Research Council of Thailand
235 The Research Chair Grant from NSTDA
236 The Center of Excellence in Clinical Virology (GCE 59-009-30-005)
237 The Centenary Academic Development Project (CU56-HR01)
238 The Ratchadaphiseksomphot Endowment Fund of Chulalongkorn University (RES560530093)
239 Office of Higher Education Commission (NRU 59-002-HR)
240 Dutsadi Piphat Scholarship.

241 **Conflict of Interest**

242 The authors have no conflicts of interest to declare.

REFERENCES

Bernal S, Palomares JC, Artura A, Parra M, Cabezas JL, Robles A, Martín

Mazuelos E. 2014. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test. *J Clin Virol* **61**:548-552 DOI 10.1016/j.jcv.2014.10.001.

Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM,

Wheeler CM. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. *J Infect Dis* **170**:1077-1085 PubMed PMID 7963696.

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L,

Guha N, Freeman C, Galichet L, Cogliano V. 2009. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. *Lancet Oncol* **10**:321-322 PubMed PMID 19350698.

Brinkman JA, Rahmani MZ, Jones WE, Chaturvedi AK, Hagensee ME. 2004. Optimization

of PCR based detection of human papillomavirus DNA from urine specimens. *J Clin Virol* **29**:230-240 PubMed PMID 15018850.

Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. 2008. Comparison of linear

array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. *J Clin Microbiol* **46**:109-117 PubMed PMID 17989194.

Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, Tresukosol D, Niruthisard S,

Trivijitsilp P, Sampatanukul P, Poovorawan Y. 2010. Prevalence and genotypes of

human papillomavirus among Thai women. *Asian Pac J Cancer Prev* **11**:117-122 PubMed
PMID 20593940.

**Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio
C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR,
Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S. 2005.** IARC HPV
Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in
cytologically normal women in the International Agency for Research on Cancer HPV
prevalence surveys: a pooled analysis. *Lancet* **366**:991-998 PubMed PMID 16168781.

Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. 1995. Human
papillomavirus testing by hybrid capture appears to be useful in triaging women with a
cytologic diagnosis of atypical squamous cells of undetermined significance. *Am J Obstet
Gynecol* **172**:946-954 PubMed PMID 7892889.

Cuschieri K, Nandwani R, McGough P, Cook F, Hogg L, Robertson C, Cubie H. 2011. Urine
testing as a surveillance tool to monitor the impact of HPV immunization programs. *J Med
Virol* **83**:1983-1987 DOI 10.1002/jmv.22183.

**Daponte A, Pournaras S, Mademtzis I, Hadjichristodoulou C, Kostopoulou E,
Maniatis AN, Messinis IE. 2006.** Evaluation of high-risk human papillomavirus types PCR
detection in paired urine and cervical samples of women with abnormal cytology. *J Clin
Virol* **36**:189-193 PubMed PMID 16690350.

De Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995.
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly
conserved sequences improves human papillomavirus detection by PCR. *J Gen Virol*
76:1057-1062 PubMed PMID 9049358.

De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. 2007.
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in

women with normal cytology: a meta-analysis. *Lancet Infect Dis* **7**:453-459 PubMed PMID 17597569.

De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. *Virology* **324**:17-27 PubMed PMID 15183049.

De Villiers EM. 2013. Cross-roads in the Classification of papillomaviruses. *Virology* **445**:2-10. DOI 10.1016/j.virol.2013.04.023.

D'Hauwers K, Depuydt C, Bogers JP, Stalpaert M, Vereecken A, Wyndaele JJ, Tjalma W. 2007. Urine versus brushed samples in human papillomavirus screening: study in both genders. *Asian J Androl* **9**:705-710 PubMed PMID 17712490.

Enerly E, Olofsson C, Nygård M. 2013. Monitoring human papillomavirus prevalence in urine samples: a review. *Clin Epidemiol* **5**:67-79 DOI 10.2147/CLEP.S39799.

Forslund O, Hansson BG, Rymark P, Bjerre B. 1993. Human papillomavirus DNA in urine samples compared with that in simultaneously collected urethra and cervix samples. *J Clin Microbiol* **31**:1975-1979 PubMed PMID 8396581.

Gakidou E, Nordhagen S, Obermeyer Z. 2008. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. *PLoS Med* **5**:e132 DOI 10.1371/journal.pmed.0050132.

Gupta A, Arora R, Gupta S, Prusty BK, Kailash U, Batra S, Das BC. 2006. Human papillomavirus DNA in urine samples of women with or without cervical cancer and their male partners compared with simultaneously collected cervical/penile smear or biopsy specimens. *J Clin Virol* **37**:190-194 PubMed PMID 16931139.

Hagihara M, Yamagishi Y, Izumi K, Miyazaki N, Suzuki T, Kato H, Nishiyama N, Koizumi Y, Suematsu H, Mikamo H. 2016. Comparison of initial stream urine samples and cervical samples for detection of human papillomavirus. *J Infect Chemother* **22**:559-562 DOI 10.1016/j.jiac.2016.05.009.

- 317 **Hagiwara M, Sasaki H, Matsuo K, Honda M, Kawase M, Nakagawa H. 2007.** Loop-
318 mediated isothermal amplification method for detection of human papillomavirus type 6,
319 11,16, and 18. *J Med Virol* **79**:605-615 PubMed PMID 17385684.

- 320 **Juan Du, Xiaonian Lu, Jun Liang, Yongsheng Yang, Jinran Lin, Xiaohua Zhu and Jinhua**
321 **Xu. 2013.** Detection and typing of human papillomavirus (HPV) in condyloma
322 acuminatum and bowenoid papulosis HybriBio HPV GenoArray test kit, real-time
323 polymerase chain reaction (PCR) and sequencing. *Afr J Pharm Pharmacol* **7**:73-77 DOI
324 10.5897/AJPP12.482.

- 325 **Kantathavorn N, Mahidol C, Sritana N, Sricharunrat T, Phoolcharoen N, Auewarakul C,**
326 **Teerayathanakul N, Taepisitpong C, Saeloo S, Sornsamdang G,**
327 **Udomchaiprasertkul W, Krongthong W, Arnarnwong A. 2015.** Genotypic distribution
328 of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women
329 undergoing cervical cancer screening programs. *Infect Agent Cancer* **10**:7 DOI
330 10.1186/s13027-015-0001-5.

- 331 **Koutsky L. 1997.** Epidemiology of genital human papillomavirus infection. *Am J Med* **102**:3-8
332 PubMed PMID 9217656.

- 333 **Kubota T, Ishi K, Suzuki M, Utsuno S, Igari J. 1998.** Usefulness of hybrid capture HPV DNA
334 assay as a diagnostic tool for human papillomavirus infection. *Kansenshogaku Zasshi*
335 **72**:1219-1224 PubMed PMID 9884509.

- 336 **Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, Yood MU,**
337 **Gilbert J, Taplin SH. 2005.** Cervical cancer in women with comprehensive health care
338 access: attributable factors in the screening process. *J Natl Cancer Inst* **97**:675-683
339 PubMed PMID 15870438.

- 340 **Li J, Mei J, Wang X, Hu L, Lin Y, Yang P. 2012.** Human papillomavirus type-specific
- 341 prevalence in women with cervical intraepithelial neoplasm in Western China. *J Clin*
- 342 *Microbiol* **50**:1079-1081. DOI 10.1128/JCM.06214-11.
- 343 **Liu SS, Leung RC, Chan KK, Cheung AN, Ngan HY. 2010.** Evaluation of a newly developed
- 344 GenoArray human papillomavirus (HPV) genotyping assay and comparison with the
- 345 Roche Linear Array HPV genotyping assay. *J Clin Microbiol* **48**:758-64 DOI
- 346 10.1128/JCM.00989-09.
- 347 **Mählck CG, Jonsson H, Lenner P. 1994.** Pap smear screening and changes in cervical cancer
- 348 mortality in Sweden. *Int J Gynaecol Obstet* **44**:267-272 PubMed
- 349 PMID 7909766.
- 350 **Munoz M, Camargo M, Soto-De Leon SC, Sanchez R, Parra D, Pineda AC, Sussmann O,**
- 351 **Perez-Prados A, Patarroyo ME, Patarroyo MA. 2013.** Human papillomavirus
- 352 detection from human immunodeficiency virus-infected Colombian women's paired
- 353 urine and cervical samples. *PLoS One* **8**:e56509 DOI 10.1371/journal.pone.0056509.
- 354 **Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ,**
- 355 **Meijer CJ. 2003.** International Agency for Research on Cancer Multicenter Cervical
- 356 Cancer Study Group. Epidemiologic classification of human papillomavirus types
- 357 associated with cervical cancer. *N Engl J Med* **348**:518-527 PubMed PMID 12571259
- 358 **Nilyanimit P, Wanlapakorn N, Niruthisard S, Pohthipornthawat N, Karalak A,**
- 359 **Laowahutanont P, Phanuphak N, Gemma N, Poovorawan Y. 2013.** Detection of
- 360 human papillomavirus in male and female urine by electrochemical DNA chip and PCR
- 361 sequencing. *Asian Pac J Cancer Prev* **14**:5519-5525 PubMed PMID 24175852.
- 362 **Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya**
- 363 **K, Yamada N, Hamada H, Yoshikawa H. 2009.** Human papillomavirus infections

- among Japanese women: age-related prevalence and type-specific risk for cervical cancer. *Cancer Sci* **100**:1312-1316 DOI 10.1111/j.1349-7006.2009.01161.x.
- Prusty BK, Kumar A, Arora R, Batra S, Das BC. 2005.** Human papillomavirus (HPV) DNA detection in self-collected urine. *Int J Gynaecol Obstet* **90**:223-227 PubMed PMID 16043176.
- Safaeian M, Solomon D, Castle PE. 2007.** Cervical cancer prevention—cervical screening: science in evolution. *Obstet Gynecol Clin North Am* **34**:739-760 PubMed PMID 18061867.
- Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. 2012.** ACS-ASCCP-ASCP Cervical Cancer Guideline Committee.. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. **62**:147-172. DOI 10.3322/caac.21139.
- Sriamporn S, Khuhaprema T, Parkin M. 2006.** Cervical cancer screening in Thailand: an overview. *J Med Screen* **1**:S39-43 PubMed PMID 17227641.
- Strauss S, Jordens JZ, McBride D, Sonnex C, Edwards S, Desselberger U, Watt P, Gray JJ. 1999.** Detection and typing of human papillomavirus DNA in paired urine and cervical scrapes. *Eur J Epidemiol* **15**:537-543 PubMed PMID 10485346.
- Sukvirach S, Smith JS, Tunsakul S, Muñoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, Snijders PJ, Coursaget P, Franceschi S, Herrero R. 2003.** Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. *J Infect Dis* **187**:1246-1256 PubMed PMID 12696004.

- 388 **Takehara K, Toda T, Nishimura T, Sakane J, Kawakami Y, Mizunoe T, Nishiwaki M,**
389 **Taniyama K. 2011.** Human papillomavirus types 52 and 58 are prevalent in uterine
390 cervical squamous lesions from Japanese women. *Patholog Res Int* **2011**:246936 DOI
391 10.4061/2011/246936.

- 392 **Van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. 2006.** Evaluation of
393 the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche
394 linear array HPV genotyping test. *J Clin Microbiol* **44**:3122-3129 PubMed PMID
395 16954236

- 396 **Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, De Coster I, Ieven**
397 **M, Van Damme P. 2014.** Optimization of HPV DNA detection in urine by improving
398 collection, storage, and extraction. *Eur J Clin Microbiol Infect Dis* **33**:2005-2014 DOI
399 10.1007/s10096 014-2147-2.

- 400 **WHO. 2013.** WHO guidelines for screening and treatment of precancerous lesions for cervical
401 cancer prevention. World Health Organization, Geneva, Switzerland.

- 402 **Ye J, Cheng X, Chen X, Ye F, Lü W, Xie X. 2010.** Prevalence and risk profile of cervical
403 Human papillomavirus infection in Zhejiang Province, southeast China: a population-
404 based study. *Viol J* **7**:66 DOI 10.1186/1743-422X-7-66.

TABLES

- 406 **Table 1.** Detection of HPV genotypes and concordance between cervical swab and urine samples.
- 407 **Table 2.** Studies of human papillomavirus DNA detected in paired urine and cervical samples
408 from females of all ages.
- 409 **Table 3.** Number of HPV genotypes detected using the HPV GenoArray assay.

Table 1(on next page)

Table 1. Detection of HPV genotypes and concordance between cervical swab and urine samples.

Table 1. Detection of HPV genotypes and concordance between cervical swab and urine

2samples.

3

Cytology	Specimen (% positive)				Concordance (percentage)
	Any HPV positive		HPV16&18		
	Cervical swab	Urine	Cervical swab	Urine	
Normal (N=95)	11 (11.6)	10 (10.5)	1 (1.1)	4 (4.2)	68 (71.6)
LSIL (N=50)	35 (10.0)	35 (10.0)	11 (22.0)	13 (26.0)	31 (62.0)
HSIL (N=19)	19 (100.0)	8 (42.1)	8 (42.1)	3 (15.8)	8 (70.5)
Total (N=164)	65 (39.6)	53 (32.3)	20 (12.2)	20 (12.2)	107 (65.2)

Table 2(on next page)

Table 2. Studies of human papillomavirus DNA detected in paired urine and cervical samples from females of all ages.

Table 2. Studies of human papillomavirus DNA detected in paired urine and cervical samples from females of all ages.

Author	Country	HPV detection assay	Age, years range	Total sample size	Lesion/HPV types	Sensitivity (%)	Specificity (%)	Concordance (%)
Struss et al. (1999)	UK	PCR with MY and GP primers	16–57	144	All/any type	76.4	73.3	75.7
Daponte et al. (2006)	Greece	In house type-specific primers and commercial	N/A	77	All/HPV16/18	70.3	100.0	85.7
Gupta et al. (2006)	India	In house L1 consensus primers	N/A	30	All/any type	100.0	100.0	100.0
Cuschieri et al. (2011)	UK	HPV INNO–LiPA	16–25	90	All/any type	90.5	67.6	59.8
Nilyanimit et al. (2013)	Thailand	Electrochemical DNA chip	27–61	116	All/HR-HPV	64.3	100.0	75
Bernal et al. (2014)	Spain	Cobas 4800HPV test	21–65	125	All/any type	90.5	85	88
Hagihara et al. (2016)	Japan	Anyplex II HPV28	19–58	240	All/any type	68.4	99.9	98.4
This study	Thailand	Hybribio GenoArray	19–69	164	All/any type	56.5	70.6	65.2

2
3 N/A, not applicable.
4
5
6

Table 3(on next page)

Table 3. Number of HPV genotypes detected using the HPV GenoArray assay.

Table 3. Number of HPV genotypes detected using the HPV GenoArray assay.

Table 3. Number of HPV genotypes detected using the HPV GenoArray assay.

No. of HPV genotypes detected	Normal (N=95)		Abnormal (N=69)	
	Cervical swab	Urine	Cervical swab	Urine
0 ^a	84 (88.4)	85 (89.5)	15 (21.7)	26 (37.7)
1	11 (11.5)	9 (9.4)	36 (52.2)	31 (44.9)
2	-	1 (1.1)	14 (20.3)	7 (10.1)
≥3	-	-	4 (5.8)	5 (7.3)

2 ^a samples were HPV DNA-negative

3